Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:11:58.516Z.
Calculation as of: 2026-10-06T21:11:58.516Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Gain Therapeutics, Inc.
Market Cap
$71.23M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$70.63M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$72.32M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$72.83M
Operating Cash Flow Yield
N/A
TTM Avg
0.41%
3Y Avg
0.41%
5Y Avg
0.41%
Market Cap
$69.61M
Operating Cash Flow Yield
N/A
TTM Avg
6.78%
3Y Avg
5.38%
5Y Avg
6.29%
Market Cap
$68.90M
Operating Cash Flow Yield
28.42%
TTM Avg
14.79%
3Y Avg
25.12%
5Y Avg
21.02%
Market Cap
$68.10M
Operating Cash Flow Yield
184.91%
TTM Avg
137.45%
3Y Avg
137.45%
5Y Avg
137.45%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.23M | N/A | N/A | N/A | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A | 0.41% | 0.41% | 0.41% |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | 6.78% | 5.38% | 6.29% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 28.42% | 14.79% | 25.12% | 21.02% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 184.91% | 137.45% | 137.45% | 137.45% |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
